XML 16 R45.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Reconciliation of revenue from segments to consolidated
The following tables present our segment information (in thousands):

 
Services
 
True Health
 
Intersegment
Eliminations
 
Consolidated
Revenue
 
 
 
 
 
 
 
For the Three Months Ended March 31, 2020
 
 
 
 
 
 
 
Services:
 
 
 
 
 
 
 
Transformation services
$
5,238

 
$
—

 
$
—

 
$
5,238

Platform and operations services
216,195

 
—

 
(6,295
)
 
209,900

Services revenue
221,433

 
—

 
(6,295
)
 
215,138

True Health:
 
 
 
 
 
 
 
Premiums
—

 
32,387

 
(240
)
 
32,147

Total revenue
$
221,433

 
$
32,387

 
$
(6,535
)
 
$
247,285

 
 
 
 
 
 
 
 
For the Three Months Ended March 31, 2019
 
 
 
 
 
 
 
Services:
 
 
 
 
 
 
 
Transformation services
$
3,353

 
$
—

 
$
—

 
$
3,353

Platform and operations services
150,351

 
—

 
(3,059
)
 
147,292

Services revenue
153,704

 
—

 
(3,059
)
 
150,645

True Health:
 
 
 
 
 
 
 
Premiums
—

 
47,376

 
(265
)
 
47,111

Total revenue
$
153,704

 
$
47,376

 
$
(3,324
)
 
$
197,756

 
 
 
 
 
 
 
 
 
Services
 
True Health
 
Segments Total
 
 
For the Three Months Ended March 31, 2020
 
 
 
 
 
 
 
Adjusted EBITDA
$
3,876

 
$
(249
)
 
$
3,627

 
 
 
 
 
 
 
 
 
 
For the Three Months Ended March 31, 2019
 
 
 
 
 
 
 
Adjusted EBITDA
$
(15,499
)
 
$
721

 
$
(14,778
)
 
 
Reconciliation of Adjusted EBITDA to net income (loss)
The following table presents our reconciliation of segments total Adjusted EBITDA to net loss attributable to Evolent Health, Inc. (in thousands):
 
For the Three Months Ended March 31,
 
2020
 
2019
Net loss attributable to common shareholders of Evolent Health, Inc.
$
(78,752
)
 
$
(46,739
)
Less:
 
 
 
Interest income
919

 
1,060

Interest expense
(6,285
)
 
(3,562
)
(Provision) benefit for income taxes
(270
)
 
496

Depreciation and amortization expenses
(16,138
)
 
(14,266
)
Equity method investment impairment
(47,133
)
 
—

Loss from equity method investees
(412
)
 
(424
)
Loss on disposal of assets
(6,447
)
 
—

Change in fair value of contingent consideration and indemnification asset
3,818

 
(100
)
Other income (expense), net
(71
)
 
427

Net loss attributable to non-controlling interests
—

 
1,910

Purchase accounting adjustments
—

 
(596
)
Stock-based compensation expense
(3,508
)
 
(4,537
)
Severance costs
(6,103
)
 
(10,602
)
Amortization of contract cost assets
(440
)
 
(754
)
Acquisition costs
(309
)
 
(1,013
)
Adjusted EBITDA
$
3,627

 
$
(14,778
)